Whether or not future editions of USP General Chapter <797> will include recommendations for IV room automation and technology is a great question, and one that Iâ€™ve been pondering for quite some time. Iâ€™m torn as to whether or not I think adding such recommendations to a USP General Chapter is a good idea.
On one hand, I believe that pharmacy is over-regulated as it is. The amount of time spent by pharmacy personnel adhering to and documenting compliance to regulations currently in place is staggering. New regulations are frequently added to the process, but rarely, if ever taken away.
On the other hand, pharmacies refuse to utilize game-changing automation and technology even when they know it has the potential to improve operations, improve patient safety, and decrease cost. Iâ€™ve met many pharmacy directors and operations managers over the years that operate in a state of willful blindness when it comes to adoption of technology in the pharmacy.
While I donâ€™t support adding, even more, regulatory requirements to pharmacy practice, Iâ€™m in favor of increased use of pharmacy automation and technology, especially in the IV room. Itâ€™s a conundrum.
With that said, it may become a moot point as it is possible that recommendations addressing the use of iv room automation and technology will find their way into the next revision of USP General Chapter <797> Pharmaceutical Compoundingâ€”Sterile Preparations. Recent discussions with people close to the situation lead me to believe it could happen.
Should that occur, it would likely be a good thing for pharmacy practice in the long run as it would drive adoption of CSP preparation technology. Even if the Expert Compounding Committee were to recommend adoption and not mandate it, i.e. â€œshouldâ€ versus â€œshallâ€, the industry would surely take note. Recommendations that show up in <797> have a way of trickling down into other regulatory agencies as well as into the minds of inspectors and pharmacy directors. For example, the 2015 California Lawbook for Pharmacy(1) states that â€œThe board shall review any formal revision to General Chapter 797 of the United States Pharmacopeia and The National Formulary (USPâ€“NF), relating to the compounding of sterile preparations, not later than 90 days after the revision becomes official, to determine whether amendments are necessaryâ€. Regardless of whether or not the board takes action, they are sure to take notice.
It’s too early to say whether or not the revisions to Chapter <797>Â will include recommendations for CSP preparation technology, but I suspect we won’t have to wait long to find out. Chapter <797> is currently up for public comment until January 31, 2016. Based on recent changes to USP General Chapter <800>, I suspect revisions to Chapter <797> will become official in a similar timeframe so that the chapters can be properly harmonized. Only time will tell.
Something worth thinking about.
(1) Article 7.5, Section 4127(c)